A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)-Reference-Cited by-同舟云学术

A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)

Published:2014-07-07 Issue:7 Volume:10 Page:2005-2014
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Esposito Susanna¹,Prymula Roman²³,Zuccotti Gian Vincenzo⁴,Xie Fang⁵,Barone Michelangelo⁵,Dull Peter M⁵,Toneatto Daniela⁵

Affiliation:

1. Pediatric Highly Intensive Care Unit; Department of Pathophysiology and Transplantation; University of Milan, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Milan, Italy

2. University Hospital Hradec Kralove; Hradec Kralove, Czech Republic

3. Charles University; Faculty of Medicine in Hradec Kralove; Hradec Kralove, Czech Republic

4. Departments of Paediatrics and Clinical sciences; University of Milan; Milan, Italy

5. Novartis Vaccines and Diagnostics; Cambridge, MA USA

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.4161/hv.29218

Reference17 articles.

2. Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

3. Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

4. Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review;Human Vaccines & Immunotherapeutics;2024-09-12

2. Arginine-linked HPV-associated E7 displaying bacteria-derived outer membrane vesicles as a potent antigen-specific cancer vaccine;Journal of Translational Medicine;2024-04-22

3. Recent advances in various bio-applications of bacteria-derived outer membrane vesicles;Microbial Pathogenesis;2023-12

4. Outer Membrane Vesicle Vaccine Platforms;BioDrugs;2023-10-05

5. Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review;Human Vaccines & Immunotherapeutics;2023-08